JP2016527221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527221A5 JP2016527221A5 JP2016526518A JP2016526518A JP2016527221A5 JP 2016527221 A5 JP2016527221 A5 JP 2016527221A5 JP 2016526518 A JP2016526518 A JP 2016526518A JP 2016526518 A JP2016526518 A JP 2016526518A JP 2016527221 A5 JP2016527221 A5 JP 2016527221A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- targeting moiety
- mutant
- beta
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 19
- 230000008685 targeting Effects 0.000 claims 10
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 3
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 102000005861 leptin receptors Human genes 0.000 claims 2
- 108010019813 leptin receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 1
- 102000039996 IL-1 family Human genes 0.000 claims 1
- 108091069196 IL-1 family Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306047 | 2013-07-19 | ||
| EP13306047.5 | 2013-07-19 | ||
| PCT/EP2014/064283 WO2015007542A1 (en) | 2013-07-19 | 2014-07-04 | Targeted modified il-1 family members |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527221A JP2016527221A (ja) | 2016-09-08 |
| JP2016527221A5 true JP2016527221A5 (enExample) | 2017-08-10 |
| JP6475713B2 JP6475713B2 (ja) | 2019-02-27 |
Family
ID=48874235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526518A Active JP6475713B2 (ja) | 2013-07-19 | 2014-07-04 | 標的修飾ｉｌ−１ファミリーメンバー |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9932409B2 (enExample) |
| EP (1) | EP3022226B1 (enExample) |
| JP (1) | JP6475713B2 (enExample) |
| KR (1) | KR102275090B1 (enExample) |
| CN (1) | CN105612180B (enExample) |
| AU (1) | AU2014292377B2 (enExample) |
| BR (1) | BR112016001128A2 (enExample) |
| CA (1) | CA2918518C (enExample) |
| DK (1) | DK3022226T3 (enExample) |
| ES (1) | ES2714504T3 (enExample) |
| IL (1) | IL243466B (enExample) |
| MX (1) | MX370348B (enExample) |
| SG (1) | SG11201600167SA (enExample) |
| WO (1) | WO2015007542A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3002674A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| MX2018005348A (es) | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para transduccion de tumores. |
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| CN116769054A (zh) | 2016-02-05 | 2023-09-19 | 奥里尼斯生物科学私人有限公司 | 双特异性信号传导剂及其用途 |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CN109563141A (zh) | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| EP3454887B1 (en) | 2016-05-13 | 2021-01-20 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
| CN110114368B (zh) | 2016-10-24 | 2024-08-02 | 奥睿尼斯生物科学私人有限公司 | 靶向突变干扰素-γ及其用途 |
| EP3577133A1 (en) | 2017-02-06 | 2019-12-11 | Orionis Biosciences NV | Targeted chimeric proteins and uses thereof |
| WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| JP7660343B2 (ja) * | 2017-03-03 | 2025-04-11 | オブシディアン セラピューティクス， インコーポレイテッド | 免疫療法のための組成物及び方法 |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| CN119285770A (zh) | 2017-08-09 | 2025-01-10 | 奥里尼斯生物科学有限公司 | Pd-1和pd-l1结合剂 |
| JP7347899B2 (ja) | 2017-08-09 | 2023-09-20 | オリオンズ バイオサイエンス インコーポレイテッド | Ｃｄ８結合物質 |
| CN117924493A (zh) | 2017-08-09 | 2024-04-26 | 奥里尼斯生物科学有限公司 | Clec9a结合剂及其用途 |
| EP3733716A4 (en) * | 2017-12-26 | 2021-11-24 | Nanjing GenScript Biotech Co., Ltd. | DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE |
| WO2019148089A1 (en) | 2018-01-26 | 2019-08-01 | Orionis Biosciences Inc. | Xcr1 binding agents and uses thereof |
| MX2020008208A (es) | 2018-02-05 | 2020-11-09 | Orionis Biosciences Inc | Agentes de unión a fibroblastos y uso de estos. |
| US12084497B2 (en) | 2018-08-08 | 2024-09-10 | Orionis Biosciences, Inc. | SIRP1α targeted chimeric proteins and uses thereof |
| US12410225B2 (en) | 2018-11-08 | 2025-09-09 | Orionis Biosciences, Inc | Modulation of dendritic cell lineages |
| US12351614B2 (en) | 2019-03-28 | 2025-07-08 | Orionis Biosciences, Inc. | CLEC9A-based chimeric protein complexes |
| JP7689079B2 (ja) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | 治療用インターフェロンアルファ１タンパク質 |
| US20230293652A1 (en) * | 2020-07-07 | 2023-09-21 | Orionis Biosciences, Inc. | Immunostimulatory adjuvants |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU632372B2 (en) | 1989-08-22 | 1992-12-24 | Immunex Corporation | Fusion proteins comprising gm-csf and il-3 |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) * | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| WO2001029870A1 (en) * | 1999-10-21 | 2001-04-26 | Sarnoff Corporation | Bi-potential electrode space-saving cathode ray tube |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| US7947265B2 (en) | 2006-08-02 | 2011-05-24 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| JP2010531666A (ja) * | 2007-06-26 | 2010-09-30 | ユニバーシティ オブ マイアミ | 抗体−エンドスタチン融合タンパク質及びそのバリアント |
| KR101661770B1 (ko) | 2007-09-21 | 2016-10-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함 |
| US8334101B2 (en) * | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| JP2012510806A (ja) | 2008-12-08 | 2012-05-17 | コンプリクス エン ヴェー | 単鎖逆平行コイルドコイルタンパク質 |
| PE20120630A1 (es) * | 2009-08-17 | 2012-05-26 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| US20130115189A1 (en) * | 2009-09-10 | 2013-05-09 | Cytos Biotechnology Ag | Use of Interleukin-1 Beta Mutein Conjugates in the Treatment of Diabetes |
| WO2012170072A1 (en) | 2011-06-06 | 2012-12-13 | Immungene, Inc. | Engineered antibody-tnfsf member ligand fusion molecules |
| CN104203982B (zh) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| US9492562B2 (en) | 2012-01-20 | 2016-11-15 | Vib Vzw | Targeted human-interferon fusion proteins |
| PL2822575T3 (pl) | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
-
2014
- 2014-07-04 MX MX2016000723A patent/MX370348B/es active IP Right Grant
- 2014-07-04 DK DK14735574.7T patent/DK3022226T3/en active
- 2014-07-04 ES ES14735574T patent/ES2714504T3/es active Active
- 2014-07-04 SG SG11201600167SA patent/SG11201600167SA/en unknown
- 2014-07-04 CN CN201480040652.6A patent/CN105612180B/zh active Active
- 2014-07-04 EP EP14735574.7A patent/EP3022226B1/en active Active
- 2014-07-04 CA CA2918518A patent/CA2918518C/en active Active
- 2014-07-04 US US14/905,352 patent/US9932409B2/en active Active
- 2014-07-04 JP JP2016526518A patent/JP6475713B2/ja active Active
- 2014-07-04 KR KR1020167002679A patent/KR102275090B1/ko active Active
- 2014-07-04 BR BR112016001128-7A patent/BR112016001128A2/pt not_active Application Discontinuation
- 2014-07-04 AU AU2014292377A patent/AU2014292377B2/en active Active
- 2014-07-04 WO PCT/EP2014/064283 patent/WO2015007542A1/en not_active Ceased
-
2016
- 2016-01-05 IL IL24346616A patent/IL243466B/en active IP Right Grant
-
2018
- 2018-02-21 US US15/901,545 patent/US20180186894A1/en not_active Abandoned
-
2019
- 2019-03-21 US US16/360,793 patent/US20190202934A1/en not_active Abandoned
-
2020
- 2020-04-28 US US16/860,660 patent/US20200255545A1/en not_active Abandoned
-
2023
- 2023-02-01 US US18/163,026 patent/US20230235086A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527221A5 (enExample) | ||
| JP2016529232A5 (enExample) | ||
| PH12022550194A1 (en) | Anti-gitr antibodies and methods of use thereof | |
| EP4276114A3 (en) | Cd20 binding single domain antibodies | |
| MX2022003249A (es) | Anticuerpos anti receptor del factor de necrosis tumoral 2 (tnfr2) y métodos de uso. | |
| CY1124456T1 (el) | Antισωματα αντι-5τ4 και συζευγματα φαρμακου αντισωματων | |
| JP2018515474A5 (enExample) | ||
| NZ599875A (en) | Human il-23 antigen binding proteins | |
| MX370348B (es) | Miembros de la familia il-1 modificados dirigidos. | |
| PH12014502527A1 (en) | St2 antigen binding proteins | |
| WO2012149412A3 (en) | Anti-endoglin (cd105) antibodies, immunoconjugates, and uses thereof | |
| MX384026B (es) | Terapeuticos de anticuerpo que se unen a ctla4. | |
| NZ626610A (en) | Antibodies that bind csf1r | |
| EA201200549A1 (ru) | Dll4-связывающие молекулы | |
| BR112012024713A2 (pt) | "anticorpo humanizado, anticorpo monoclonal humanizado ou fragmento de anticorpo, seus usos, polinucleotídeo isolado, e composição farmacêutica" | |
| WO2015108998A3 (en) | Cartilage targeting agents and their use | |
| BR112012028920A2 (pt) | formulações de anticorpo de alta concentração | |
| EA201300311A1 (ru) | Vegf-связывающие молекулы | |
| EP4311558A3 (en) | Antibodies that bind il-23 | |
| EP4183806A3 (en) | Glycan-interacting compounds and methods of use | |
| HRP20221490T1 (hr) | Poboljšanje antitumorskog odgovora t stanice | |
| EA201401065A1 (ru) | Ang2-связывающие молекулы | |
| PH12019502007A1 (en) | Anti-gitr antibodies and methods of use thereof | |
| WO2015058861A8 (en) | Bispecific constructs and their use in the treatment of various diseases | |
| EP2552961A4 (en) | HUMANIZED ANTIBODIES TO IL-25 |